CD8A and neoplasm: It has been thought that cGAMP-enhanced cross-presentation of tumor-associated antigens in DCs to CD8+ cytotoxic T cells is one of the mechanisms underlying STING ligand–induced antitumor immunity (Wang et al, 2017).